HealthCare Global Enterprises Limited reported a significant improvement in profitability for the quarter ended June 30, 2026, with consolidated net profit (after tax and exceptional items) rising to ₹1,646 lakhs from ₹598 lakhs in the corresponding quarter ended June 30, 2025. The results were reviewed by the audit committee and approved by the board of directors at their meeting held on August 06, 2026.

Consolidated Financial Performance

On a consolidated basis, total income for the quarter ended June 30, 2026 grew to ₹70,723 lakhs, compared to ₹61,999 lakhs in the corresponding quarter ended June 30, 2025, and ₹66,540 lakhs in the preceding quarter ended March 31, 2026. Net profit before tax and exceptional items stood at ₹2,503 lakhs for the quarter, compared to ₹1,192 lakhs in the year-ago quarter and ₹3,316 lakhs in the preceding quarter. No exceptional items were recorded in the quarter ended June 30, 2026, unlike the preceding quarter ended March 31, 2026, which had a net exceptional loss of ₹3,191 lakhs.

The net profit attributable to equity shareholders of the company on a consolidated basis was ₹1,377 lakhs for the quarter ended June 30, 2026, compared to ₹475 lakhs in the corresponding quarter ended June 30, 2025 and ₹217 lakhs in the preceding quarter ended March 31, 2026. Total comprehensive income attributable to equity shareholders stood at ₹1,424 lakhs for the quarter.

The following table summarises the consolidated financial results:

Standalone Financial Performance

On a standalone basis, HealthCare Global Enterprises reported total income of ₹38,622 lakhs for the quarter ended June 30, 2026, up from ₹33,503 lakhs in the corresponding quarter ended June 30, 2025 and ₹36,513 lakhs in the preceding quarter ended March 31, 2026. Net profit before tax and exceptional items was ₹748 lakhs, compared to ₹524 lakhs in the year-ago quarter. Net profit after tax and exceptional items stood at ₹558 lakhs, against ₹345 lakhs in the corresponding quarter ended June 30, 2025 and ₹153 lakhs in the preceding quarter ended March 31, 2026.

The following table summarises the standalone financial results:

Earnings Per Share

On a consolidated basis, basic and diluted earnings per share (of ₹10 each) for the quarter ended June 30, 2026 stood at ₹0.92 each, compared to ₹0.34 (basic) and ₹0.33 (diluted) in the corresponding quarter ended June 30, 2025. On a standalone basis, basic and diluted EPS for the quarter were ₹0.37 each, against ₹0.25 (basic) and ₹0.24 (diluted) in the year-ago quarter. The equity share capital remained unchanged at ₹14,930 lakhs for the quarter ended June 30, 2026, compared to ₹13,942 lakhs in the corresponding quarter ended June 30, 2025.

Notes and Disclosures

The financial results represent an extract from the detailed format of quarterly financial results filed with the stock exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The figures for the preceding quarter ended March 31, 2026 are balancing figures between audited figures for the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous financial year, which were subject to limited review by the statutory auditors. The full format of the quarterly financial results is available on the websites of NSE Limited, BSE Limited, and the company's website.

Healthcare Global Enterprises delivered a robust start to FY27, reporting consolidated revenue of ₹6,951 million in Q1FY27, a 13% year-on-year increase driven by an 11% surge in patient volumes. The company’s adjusted EBITDA grew 20% to ₹1,339 million, expanding margins to 19.4% from 18.2% in Q1FY26, while profit after tax (PAT) surged 190% to ₹138 million. This performance highlights the strength of its integrated oncology model and the successful ramp-up of new capacity, particularly the North Bengaluru facility which commenced operations in May 2026.

The Board of Directors approved the unaudited financial results on August 06, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results reflect broad-based growth across its South, West, and East clusters, supported by an improved payor mix where non-institutional revenue grew 17% YoY, increasing its contribution from 67% to 69%. Notably, the company divested its fertility business in June 2026, which contributed ₹169 million in revenue and ₹23 million in EBITDA during the quarter.

Financial Performance Highlights

Revenue growth was primarily volume-led, with average revenue per patient (ARPP) increasing by 2% to ₹85,943. Reported EBITDA stood at ₹1,223 million, impacted by startup losses of ₹70 million from the new North Bengaluru center and an EPCG-related provision of ₹46 million. Excluding these one-time items, adjusted EBITDA margins improved by 120 basis points year-on-year. International business revenue also grew 9% YoY to ₹208 million, driven by stronger inflows for radiation oncology and PET cases.

Regional Growth Dynamics

The West cluster remained the largest revenue contributor at 43% (₹3,010 million), growing 9% YoY on strong patient inflows in Maharashtra, though growth was moderated in Gujarat due to case-mix shifts toward medical oncology. The South cluster delivered 16% YoY growth to ₹2,765 million, led by the Bengaluru Center of Excellence and the new North Bengaluru facility. The East cluster showed the highest growth rate at 22% YoY to ₹799 million, driven by a 25% surge in patient volumes, although ARPP declined slightly due to higher participation from state government schemes.

Strategic Expansion and Capacity Additions

Healthcare Global Enterprises added 121 operational beds in Q1FY27, bringing total operational beds to 2,855. Key additions included 56 beds at North Bengaluru, 26 at Ranchi, and smaller increments across Borivali, Nashik, Hubli, and Kenya. The company commissioned an MR-LINAC at North Bengaluru in July 2026, enhancing its adaptive radiation therapy capabilities. Additionally, Rajkot was upgraded to a Comprehensive Cancer Care Centre with a new LINAC, and robotic surgery capabilities were strengthened at Nashik and Bengaluru.

What the Numbers Show

The divergence between reported and adjusted EBITDA highlights the transitional costs associated with aggressive capacity expansion. While startup losses at North Bengaluru pressured reported margins, the underlying operational efficiency is evident in the 20% growth in adjusted EBITDA versus only 13% revenue growth. This suggests successful operating leverage as fixed costs are spread over a larger patient base. Furthermore, the shift in payor mix towards cash and TPA (now 66% combined vs 63% in FY25) supports the margin expansion narrative, indicating a strategic move away from lower-margin government schemes in key markets.